Table 2
Coexpression of the oestrogen receptor (ER) and a proliferation marker (Ki67) in breast lesions associated with no or a low increased risk of subsequently developing breast cancer
| Lesions | Mean age (SD) | No. of cases | Mean no. cells counted (SD) | Mean % ER positive cells (SD) | Mean % Ki67 positive cells (SD) | Mean % dual positive cells (SD) | Mean % dual positive cells expected (SD) | Mean observed /expected ratio (SD) | Mean % of total Ki67 that are ER+ (SD) |
|---|---|---|---|---|---|---|---|---|---|
| *Data from Shoker et al.9 | |||||||||
| *Normal (premenopausal) | 42 (10) | 14 | 1475 (885) | 6.8 (5.4) | 2.6 (3.1) | 0.01 (0.02) | 0.17 (0.37) | 0.05 (0.14) | 0.44 (1.44) |
| *Normal (postmenopausal) | 65 (7.5) | 14 | 1099 (328) | 42 (23) | 0.34 (0.33) | 0.04 (0.05) | 0.11 (0.12) | 0.39 (0.52) | 11 (20) |
| Lactation | 29 (5.8) | 10 | 1623 (353) | 1.33 (1.15) | 2.5 (2.6) | 0.01 (0.03) | 0.03 (0.03) | 0.02 (0.52) | 1.03 (1.79) |
| Apocrine metaplasia | 57 (8.9) | 13 | 954 (829) | 0.0 (0.0) | 1.10 (1.06) | 0.0 (0.0) | 0.0 (0.0) | – | 0.0 (0.0) |
| Duct ectasia | 51 (15) | 10 | 915 (261) | 6.5 (9.0) | 1.57 (1.32) | 0.0 (0.0) | 0.12 (0.27) | 0.0 (0.0) | 0.0 (0.0) |
| Sclerosing adenosis | 54 (12) | 13 | 1353 (858) | 49 (24) | 1.01 (1.55) | 0.18 (0.52) | 0.37 (0.56) | 0.22 (0.31) | 12 (21) |
| Radial scar | 56 (6.6) | 13 | 2417 (946) | 44 (18) | 1.57 (1.16) | 0.28 (0.34) | 0.63 (0.50) | 0.32 (0.27) | 18 (15) |
| Papilloma | 53 (12) | 11 | 1795 (437) | 50 (18) | 3.1 (2.5) | 0.79 (0.83) | 1.60 (1.57) | 0.54 (0.32) | 21 (16) |
| Fibroadenoma | 37 (11) | 10 | 1375 (202) | 45 (23) | 4.4 (3.7) | 1.03 (1.25) | 1.92 (1.71) | 0.46 (0.33) | 25 (22) |
| Phyllodes tumour | 53 (14) | 10 | 1245 (157) | 68 (16) | 4.1 (4.0) | 1.50 (1.54) | 2.50 (2.16) | 0.44 (0.27) | 38 (18) |
| Normal male | 65 (9) | 8 | 654 (374) | 43 (29) | 0.39 (0.51) | 0.11 (0.18) | 0.18 (0.24) | 0.57 (0.56) | 38 (41) |
| Gynaecomastia | 33 (16) | 11 | 1510 (272) | 63 (23) | 1.7 (1.5) | 0.56 (0.74) | 0.96 (0.87) | 0.47 (0.32) | 33 (24) |
